EU Approves Daraxonrasib for Pancreatic Cancer via Accelerated Pathway
Published 2 d ago1 sourceEvidence: Reported
An international trial, with UChicago Medicine among U.S. sites, reports that the experimental drug daraxonrasib doubled average survival in patients with advanced pancreatic cancer. The finding is preliminary and not yet peer-reviewed or regulatory-approved, but it represents a notable potential advance against a disease with poor prognosis. Uncertainty remains on safety, durability, and whether the benefit extends beyond the studied subgroup.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Locations
Entities
Published 2 d ago1 sourceEvidence: Reported
Published 3 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 3 d ago1 sourceEvidence: Reported
Published 3 d ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 6 h ago1 sourceEvidence: Reported